Robert Lee Butchofsky
Fondatore presso Mati Therapeutics, Inc.
Provenienza dei contatti di primo grado di Robert Lee Butchofsky
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
QLT, Inc.
 QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada.
52
| Extinct | Miscellaneous Commercial Services | 52 |
Mati Therapeutics, Inc.
 Mati Therapeutics, Inc. BiotechnologyHealth Technology Mati Therapeutics, Inc. operates as biotechnology company. It develops non-invasive sustained drug delivery platform to treat ocular diseases, in particular glaucoma. The company was founded by Robert Lee Butchofsky and Christopher A. Muller and is headquartered in Austin, TX.
3
| Private Company | Biotechnology | 3 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Robert Lee Butchofsky tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | General Counsel Director of Finance/CFO | |
| IMMUNOMEDICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Inamed Corp.
 Inamed Corp. Medical SpecialtiesHealth Technology Inamed Corp. developed and manufactured breast implants, wrinkle prevention & obesity solutions. Its products were available through its two business divisions: INAMED Aesthetics, and INAMED Health. The company offered breast implants for augmentation, reconstruction surgeries, invasive surgeries for sustained weight loss and other dermal products to correct facial wrinkles. INAMED was headquartered in Santa Barbara, CA. | Medical Specialties | Director of Finance/CFO Director of Finance/CFO | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| LIGAND PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member | |
MedImmune Vaccines, Inc.
 MedImmune Vaccines, Inc. BiotechnologyHealth Technology MedImmune Vaccines, Inc. develops, manufactures and markets live vaccines. Its developed vaccine is inhaled FluMist. The company is located in Mountain View, CA | Biotechnology | Director/Board Member President | |
Axys Pharmaceuticals, Inc.
 Axys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Axys Pharmaceuticals, Inc. engages in the development of integrated drugs. The company is headquartered in South San Francisco, CA. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Corporate Officer/Principal | |
Renovis, Inc.
 Renovis, Inc. Pharmaceuticals: MajorHealth Technology Renovis, Inc. develops pharmaceutical products. The company discovers, develops, and commercializes novel therapeutics for neurological and inflammatory diseases. It is headquartered in San Francisco, CA | Pharmaceuticals: Major | Corporate Secretary Director/Board Member | |
| INMED PHARMACEUTICALS INC. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer General Counsel | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal | |
| ONCOMED PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Biotechnology | Chairman Chief Executive Officer | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Chairman Corporate Officer/Principal | |
| ARBUTUS BIOPHARMA CORPORATION | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer General Counsel | |
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Biotechnology | Chief Executive Officer Corporate Officer/Principal Human Resources Officer | |
CorMatrix Cardiovascular, Inc.
 CorMatrix Cardiovascular, Inc. Medical SpecialtiesHealth Technology CorMatrix Cardiovascular, Inc. develops and markets commercial medical devices. It offers CorMatrix CanGaroo, Vascular Repair, Pericardial Repair & Reconstruction, Tyke, and Cardiac Tissue Repair. The company was founded by David B. Camp and Robert G. Matheny in 2001 and is headquartered in Roswell, GA. | Medical Specialties | Director of Finance/CFO Director/Board Member | |
| SYNCONA LIMITED | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
| Dartmouth College | College/University | Masters Business Admin Undergraduate Degree | |
The Scripps Research Institute
 The Scripps Research Institute Other Consumer ServicesConsumer Services The Scripps Research Institute is a private, non-profit research organizations that performs basic biomedical research in molecular & cellular biology, chemistry, immunology and neuroscience. They receive the majority of its funding from federal agencies such as the National Institutes of Health. The organization also partners with pharmaceutical companies and is affiliated with the Scripps hospital group. The organization was founded in 1955 and is headquartered in La Jolla, California. | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
| XENON PHARMACEUTICALS INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Human Resources Officer | |
| McGill University | College/University | Undergraduate Degree Doctorate Degree | |
| University of British Columbia | College/University | Undergraduate Degree Corporate Officer/Principal Undergraduate Degree Undergraduate Degree Doctorate Degree Graduate Degree Corporate Officer/Principal | |
| Simon Fraser University | College/University | Undergraduate Degree Undergraduate Degree | |
| University of Western Ontario | College/University | Undergraduate Degree Graduate Degree | |
| University of California, Berkeley | College/University | Undergraduate Degree Masters Business Admin | |
| University of Maryland | College/University | Corporate Officer/Principal Undergraduate Degree | |
TOLMAR Therapeutics, Inc.
 TOLMAR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology TOLMAR Therapeutics, Inc. provides healthcare services. The company's products include Eligard, a prostate cancer treatment, Aczone, a dermatology product for the treatment of acne, and Atrigel, a drug delivery system. Its drug delivery systems deliver medicines such as proteins and antibiotics. The company also makes Orajel and Cepacol mouth sore medicines. It is headquartered in Fort Collins, CO. | Pharmaceuticals: Major | President Director/Board Member | |
Genome British Columbia
 Genome British Columbia Miscellaneous Commercial ServicesCommercial Services Genome British Columbia invests in and manages genomics and proteomics research projects. It offers services in human health, environment, agriculture, forestry, mining, energy, aquaculture, and fisheries. The company was founded in 2000 and is headquartered in Vancouver, Canada. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
BIOTECanada
 BIOTECanada BiotechnologyHealth Technology BIOTECanada serves as a national association for Canada's health, industrial and agricultural biotechnology sectors. The company was founded in 1986 and is headquartered in Ottawa, Canada. | Biotechnology | Director/Board Member Director/Board Member | |
viDA Therapeutics, Inc.
 viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | Biotechnology | Director/Board Member Founder | |
Valocor Therapeutics, Inc.
 Valocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Valocor Therapeutics is a clinical-stage, privately-held company dedicated to developing innovative treatments for major unmet needs in dermatology. The company's portfolio of dermatology therapeutics includes Lemuteporfin, a potent and selective topical photodynamic therapy for moderate to severe acne and a portfolio of novel, topical small molecule therapeutics targeting acne, sebaceous gland hyperactivity, skin pigmentation disorders and inflammatory skin diseases. Valocor Therapeutics is headquartered in Vancouver, British Columbia. Although many common yet serious skin conditions have unsatisfactory treatment options, dermatology has in recent years attracted limited research resources and investment. As a result, a sparse pipeline and a lack of true scientific innovation have been the dominant themes of this field for the last twenty years. During this same period, technological advances have produced new research techniques that have greatly expanded its ability to study disease processes and establish new effective therapeutic strategies. Much of this innovative research has been applied to the fields such as oncology, autoimmunity, and ocular diseases. Valocor is applying current biotechnology techniques to develop breakthrough therapies for major dermatological diseases, where prevalent conditions, minimal competition and important medical needs exist. | Pharmaceuticals: Major | Chief Executive Officer Chairman | |
| The University of North Carolina at Charlotte | College/University | Masters Business Admin Corporate Officer/Principal | |
| TRAVERE THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor | |
California Biomedical Innovation Alliance
 California Biomedical Innovation Alliance BiotechnologyHealth Technology California Biomedical Innovation Alliance provides biomedical advocacy and community services. The private company is based in South San Francisco, CA and has subsidiaries in United States. The CEO of the company is Sara Radcliffe. | Biotechnology | Director/Board Member Chairman | |
Phoenix Molecular Designs Ltd.
 Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
California Life Sciences Association
 California Life Sciences Association Miscellaneous Commercial ServicesCommercial Services California Life Sciences Association (CLSA) is the largest and most influential life sciences advocacy and business leadership organization in California. The non-profit company is based in South San Francisco, CA, and has offices in other locations as well. The company works closely with industry, government, academia, and others to shape public policy, improve access to innovative technologies, and grow California's life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors, and service providers throughout the state. Mike Guerra has been the CEO of the company since 2019. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Chairman | |
| ZYMEWORKS INC. | Pharmaceuticals: Major | Chief Executive Officer | |
ImStar Therapeutics, Inc.
 ImStar Therapeutics, Inc. BiotechnologyHealth Technology ImStar Therapeutics, Inc. develops therapies for ALS and neurodegenerative disease. The firm's lead drug candidate is IMS-088, a small-molecule compound currently in preclinical development. It is studying compounds directed at a proprietary new therapeutic target for ALS called TANA. The company was founded by Daniel J. Wattier and Jean-Pierre Julien in 2012 and is headquartered in Vancouver, Canada. | Biotechnology | Founder Chairman Director/Board Member Founder |
Statistiche
Distribuzione geografica
| Stati Uniti | 29 |
| Canada | 18 |
| Francia | 3 |
| Regno Unito | 3 |
| Israele | 2 |
Settori
| Health Technology | 34 |
| Consumer Services | 11 |
| Commercial Services | 5 |
| Utilities | 2 |
| Miscellaneous | 2 |
Posizioni
| Director/Board Member | 283 |
| Corporate Officer/Principal | 114 |
| Independent Dir/Board Member | 87 |
| Chairman | 53 |
| Director of Finance/CFO | 52 |
Contatti più connessi
| Insiders | |
|---|---|
| Alan C. Mendelson | 45 |
| Philip B. Livingston | 31 |
| Ken Galbraith | 30 |
| Kathryn Falberg | 30 |
| John Thomas | 30 |
| Paul Hastings | 25 |
| Bruce Carter | 25 |
| Joseph Turner | 22 |
| Julia G. Levy | 22 |
| Mohammad Azab | 21 |
| John Kozarich | 21 |
| Geoffrey F. Cox | 20 |
| Jason Aryeh | 18 |
| Ron D. Henriksen | 17 |
| Richard R. Vietor | 17 |
- Borsa valori
- Insiders
- Robert Lee Butchofsky
- Connessioni Società
